Top 50 Cell Line Development

This biopharmaceutical company develops a platform that optimizes cell line development (CLD) for biomanufacturing, aiming to increase drug yields and reduce production costs. Their proprietary technology identifies the most efficient cell lines for specific biomanufacturing processes, offering end-to-end CLD services.

Opo Bio specializes in cell line development for the cultivated meat industry, providing a multi-species and multi-cell type bank that supports large-scale cell culture. By supplying optimized livestock cells, Opo Bio enables producers to enhance cultivation efficiency and reduce production costs for cultivated meat products.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

The startup develops digital cell sorting tools that integrate computer vision with cell biology to enhance drug discovery and cell line development. Their technology enables high-throughput identification and single-cell sorting, facilitating rapid B-cell screening at significantly lower costs for drug developers.

Jushu Biotech develops a high-throughput biosensing platform utilizing CRISPR-based genome editing and ultrahigh-throughput droplet microfluidics to optimize microbial and mammalian cell lines for various applications in health, biochemicals, and agriculture. The company addresses the inefficiencies in traditional cell engineering by enabling rapid iteration and selection of engineered cells, significantly enhancing production capabilities.

The startup develops genetic cell modification technology to create engineered cell lines that produce therapeutic proteins and enhance immune cell therapies. By utilizing stem cell-derived tissues to express chimeric antigen receptors, the company enables targeted cancer treatment for patients.

Prolific Machines offers a next-generation Cell Line Development platform that integrates optogenetic technology with AI-driven optimization for biomanufacturing. This Photomolecular™ platform uses light to dynamically control cellular processes, significantly boosting titers and improving consistency for difficult-to-express biotherapeutics. The system provides flexible, scalable solutions designed to lower COGS and enhance product quality across antibody and biosimilar production.

Asimov develops a platform that integrates synthetic biology, biophysical simulations, and machine learning to engineer mammalian cell lines for the production of biologics and gene therapies. This technology enables healthcare companies to optimize the design and manufacturing processes of genetic circuits, improving efficiency and scalability in therapeutic applications.

The startup develops optimized CRISPR guide RNA and edited cells for the cell biology and gene therapy research markets, offering products such as CRISPR reagents and gene knockout kits. Their solutions enable researchers to perform genome engineering more efficiently and reliably, facilitating advancements in genetic research and therapeutic applications.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

NewForm Foods utilizes cellular agriculture technology and proprietary bioprocessing to enable food producers and retailers to efficiently scale the production of cultivated meat and sustainable food products. By reducing capital and operational costs, the platform addresses the need for environmentally friendly food systems that do not compromise on taste or animal welfare.

ExpressCells specializes in the development of custom cell lines using advanced genetic engineering techniques for biological research and drug discovery. This service addresses the need for tailored cellular models that enhance experimental accuracy and accelerate the drug development process.

Alvotech specializes in the development and manufacturing of biosimilars through a vertically integrated process that includes cell line development and fill-finish manufacturing. This approach enhances access to affordable biologic medicines, addressing the high costs associated with traditional biologic therapies.

Artblood develops a cell-based system for the production of artificial blood, addressing the global shortage and adverse effects associated with traditional blood transfusions. The company also creates specialized red blood cells for antibody detection and therapeutic delivery, enhancing the safety and efficacy of transfusion-related treatments.

SecondCell Bio develops engineered human disease cell models that serve as more accurate starting points for drug discovery, delivering reliable biological data for both traditional research and AI-driven screening. By providing these custom cell platforms to pharmaceutical companies and biotech firms, they enable more predictive preclinical studies and reduce the high attrition rates in development pipelines. The company monetizes through licensing of the engineered cell lines and associated data services to its clients.

Quest develops proprietary cell lines and patented food ingredients to enable scalable and cost-effective production for the cultivated meat and alternative protein industries. Their solutions address key bottlenecks in product quality and manufacturing, facilitating the widespread adoption of sustainable protein sources.

Addy Gene specializes in CRISPR-Cas gene editing technology, offering services such as gene knockout, point mutation, and cell line construction to enhance genetic modification processes. The company improves the efficiency and precision of gene editing, enabling advancements in biotechnology and therapeutic applications for research institutions and enterprises.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.

Wheeler Bio utilizes its Portable CMC® platform to streamline the transition from drug discovery to clinical supply by offering modular development services, including mammalian cell line and process development. This approach addresses the significant delays and risks associated with the traditional drug development pipeline, enabling biopharma companies to accelerate their path to IND filing.

Proton Bio provides contract development and manufacturing organization (CDMO) services specializing in gene and cell therapy. The company focuses on producing high-quality therapeutic products to meet the growing demand for advanced treatments in genetic disorders and cancer.

Sphere Fluidics develops picodroplet microfluidic technology for high-throughput single cell analysis and isolation, enabling the screening of millions of viable cells within hours. Their solutions enhance efficiency in biologics discovery and development by providing precise, reliable data for cell engineering and synthetic biology applications.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

Hopstem is a pharmaceutical company specializing in the differentiation of human induced pluripotent stem cells (iPSCs) into neural cells, alongside cell banking and engineering services. This technology addresses the need for reliable and scalable sources of neural cells for research and therapeutic applications in neurodegenerative diseases.

Celularity is developing off-the-shelf, placental-derived allogeneic cell therapies, including mesenchymal-like adherent stromal cells and engineered T-cells, to provide scalable treatment options for aging-related diseases, cancer, and immune disorders. By utilizing the readily available postpartum placenta, Celularity addresses the need for effective and accessible cellular therapies in the healthcare market.

Extracellular is a contract development and manufacturing organization (CDMO) that specializes in biomanufacturing processes for cultivated meat and seafood, utilizing non-human cell culture technologies to produce biomass efficiently. The company addresses the challenge of scaling production in sustainable biotechnology by providing tailored cell culture media and large-scale bioreactor capabilities to accelerate time to market for its clients.

Solaris Bio develops serum-free culture media and related solutions for cell manufacturing in regenerative medicine, utilizing proprietary AI technology to enhance the safety and efficacy of cell products while reducing costs. The startup addresses the need for chemically defined and animal origin-free media formulations that optimize cell growth and differentiation for various therapeutic applications.

Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.

Genocury develops iPS-derived CAR-NKT cell therapy products using gene editing and directed differentiation technologies to provide affordable treatment options for cancer patients. The company focuses on creating off-the-shelf immune cell therapies that enhance patient access to effective cancer treatments while maintaining cost-effectiveness.

The startup manufactures immune clinical cells to facilitate cell therapy development, utilizing specialized software tools for the design, production, and analysis of these therapies. Their integrated approach combines a dedicated manufacturing facility and a team of experts, enabling researchers to expedite the delivery of effective cell therapies to patients.

ProFuse Technology specializes in muscle cell differentiation, fusion, and maturation through proprietary supplements and immortalized bovine muscle cell lines, enhancing the efficiency of cultivated meat production. Their solutions aim to increase yield, reduce production costs, and accelerate production cycles for life science and cultivated meat companies.

Astraveus is developing the Lakhesys - The Benchtop Cell Factory™, a microfluidics-powered platform that integrates hardware, software, and consumables for cell and gene therapy manufacturing. This solution enhances development throughput by up to 100 times while reducing resource consumption by 10 to 20 times, making cell therapies more accessible to patients.

SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.

Bruker Cellular Analysis provides optofluidic and proteomic barcoding technologies that enable the rapid analysis of single cells, facilitating the exploration of their phenotypic and genotypic characteristics. This approach addresses the need for efficient and precise screening in biotherapeutics and cell line development, enhancing the understanding of cellular behavior and therapeutic efficacy.

CustomCells specializes in the design and manufacturing of high-performance battery technology tailored for electric mobility applications. The company addresses the limitations of current energy storage solutions by providing scalable, customer-centric batteries that enhance the efficiency and sustainability of automotive and aviation industries.

Propagenix develops cell bioproduction platforms utilizing conditional reprogramming technology to expand epithelial cells for regenerative therapies. The company addresses the challenges of epithelial barrier tissue dysfunction and injury, providing essential tools for translational biomedical research and therapeutic applications.

This biotech company develops artificial red blood cells and a related cell line for both human and animal healthcare applications. Their technology aims to provide a readily available blood substitute for transfusions, addressing critical needs in medical and veterinary fields.

PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.

Bramante Biologics operates a contract manufacturing facility that delivers GMP‑grade biologics using a robotics‑first production line and AI‑driven quality systems. The platform enables biotech companies to run small, rapid batches with automated documentation and early risk detection, compressing clinical manufacturing timelines from months to weeks while maintaining regulatory‑level quality. Revenue is generated through fee‑for‑service contracts for batch production, process development, and associated data analytics.

Resilience is a biomanufacturing company that utilizes advanced technologies to produce complex medicines, including cell and gene therapies, while ensuring the integrity of biopharmaceutical supply chains. The company addresses the challenge of scaling production to meet the growing demand for innovative therapies by providing tailored, end-to-end manufacturing solutions.

Overland Pharmaceuticals is focused on the global development of cell therapies to treat various diseases. The company addresses the need for effective and scalable treatment options by utilizing advanced cell engineering techniques to enhance therapeutic efficacy.

Waypoint is developing a cell therapy platform that utilizes spatial multi-omics and pooled screening to optimize the design and development of therapies for solid tumors. This approach enhances the accuracy and speed of therapy development by measuring both cell-autonomous and non-autonomous effects, addressing the limitations of traditional in vitro and in vivo methods.

Cellcolabs specializes in the industrial-scale, GMP production of high-quality mesenchymal stromal cells (MSCs) for research and clinical applications. By providing these cells, the company aims to enhance the availability and affordability of MSCs, facilitating advancements in treatments for severe and incurable diseases.

This company manufactures a device for growing and imaging miniaturized cell cultures, particularly for DIC and fluorescence microscopy. They also offer cryopreservation services for brain tissue, enabling the creation of primary neuronal and glial cell cultures.

Nuwacell specializes in the research, development, and production of induced pluripotent stem cell (iPSC)-derived therapies for clinical applications. The company addresses the need for effective cell-based treatments in regenerative medicine by providing scalable and reliable cell therapy products.

Canton Biologics provides end‑to‑end contract development and manufacturing services for monoclonal antibodies, bispecific antibodies, fusion proteins, and recombinant proteins. Its portfolio includes cell line and process development platforms, GMP‑compliant manufacturing, and comprehensive quality and regulatory support. The company leverages high‑titer CHO and microbial expression systems to accelerate IND and commercial product timelines for global biopharma clients.

MedLab Essentials develops cell-based therapeutic products using advanced bioprocessing techniques to enhance the efficacy of treatments for various diseases. The company addresses the need for more effective and targeted therapies in the biotechnology sector.

CoED Biosciences provides an integrated platform for cell therapy development and manufacturing. Their system streamlines immune cell isolation, activation, and expansion from biological samples, eliminating the need for centrifuges or magnetic separation systems.